×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

GlycoMimetics Inc. (GLYC) NASDAQ

$2.96 (0.22) (-6.92%)

Market Cap: $204.95M

As of 03/28/24 10:30 AM EDT. Market open.

(GLYC)

GlycoMimetics Inc. (GLYC)
NASDAQ

$2.96
(0.22) (-6.92%)

Market Cap: $204.95M

As of 03/28/24 10:30 AM EDT. Market open.

Add to Portfolio

at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary ... read more

at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Rachel King
Full Time Employees
54
CEO Compensation (Base)
$543,000
CEO Compensation (Total)
$3.19M
URL
Address
9708 Medical Center Dr, Maryland, Rockville, 20850-3343.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Rachel King
Full Time Employees
54
CEO Compensation (Base)
$543,000
CEO Compensation (Total)
$3.19M
Address
9708 Medical Center Dr, Maryland, Rockville, 20850-3343.
PRICE CHART FOR GLYCOMIMETICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$3.07
Previous Close
$3.18
Days Range
$2.82 - $3.18
52 week range
$1.11 - $3.53
Volume
137,277
Avg. Volume (30 days)
318,894
Market Cap
$204.95M
Dividend Yield
-
P/E
-
Shares Outstanding
64,450,385
Open
$3.07
Previous Close
$3.18
Days Range
$2.82 - $3.18
52 week range
$1.11 - $3.53
Volume
137,277
Avg. Volume (30 days)
318,894
Market Cap
$204.95M
Dividend Yield
-
P/E
-
Shares Outstanding
64,450,385
FINANCIAL STATEMENTS FOR GLYCOMIMETICS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR GLYCOMIMETICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Andrews Patricia SDirectorDec 29, 2023 Option Exercise$2.365,19112,25158,608Jan 02, 2024, 04:05 PM
King Rachel K.DirectorDec 29, 2023 Option Exercise$2.364,23810,002511,860Jan 02, 2024, 04:05 PM
Goldberg Mark AlanDirectorDec 29, 2023 Option Exercise$2.365,82713,75220,244Jan 02, 2024, 04:05 PM
Goldberg Mark AlanDirectorSep 30, 2023 Option Exercise$1.509,16713,75114,417Oct 03, 2023, 04:15 PM
Rock EdwinChief Medical OfficerSep 22, 2023 Buy$1.3830,40341,956375,403Sep 25, 2023, 04:21 PM
Rock EdwinChief Medical OfficerSep 21, 2023 Buy$1.3835,00048,300345,000Sep 25, 2023, 04:21 PM
Koenig ScottDirectorJun 01, 2023 Option Exercise$0.6021,00012,60036,750Jun 02, 2023, 04:10 PM
Hahn Brian M.SVP Finance, CFOMay 17, 2023 Sale$1.953,7007,21553,143May 18, 2023, 04:27 PM
JUNIUS DANIEL MDirectorMay 10, 2023 Buy$1.5630,00046,80093,250May 11, 2023, 05:08 PM
Johnson Bruce SSVP & Chief Commercial OfficerMay 08, 2023 Buy$1.5713,50021,195138,980May 09, 2023, 05:00 PM
Invus Public Equities, L.P.10% OwnerFeb 24, 2023 Buy$1.70100,000170,0008,589,064Feb 28, 2023, 05:33 PM
Invus Public Equities, L.P.10% OwnerFeb 23, 2023 Buy$1.75200,000350,7608,489,064Feb 23, 2023, 06:23 PM
Invus Public Equities, L.P.10% OwnerFeb 22, 2023 Buy$1.79150,000268,9958,289,064Feb 23, 2023, 06:23 PM
Invus Public Equities, L.P.10% OwnerFeb 21, 2023 Buy$1.8550,00092,5008,139,064Feb 23, 2023, 06:23 PM
Invus Public Equities, L.P.10% OwnerFeb 17, 2023 Buy$1.71200,000341,0008,089,064Feb 17, 2023, 05:29 PM
Invus Public Equities, L.P.10% OwnerFeb 16, 2023 Buy$1.68315,266531,1297,889,064Feb 17, 2023, 05:29 PM
Invus Public Equities, L.P.10% OwnerFeb 15, 2023 Buy$2.161,000,0002,155,8007,573,798Feb 17, 2023, 05:29 PM
Invus Public Equities, L.P.10% OwnerFeb 09, 2023 Buy$3.2411,45137,1236,573,798Feb 13, 2023, 05:45 PM
Koenig ScottDirectorJan 27, 2023 Option Exercise$2.5510,50026,77515,750Jan 30, 2023, 04:13 PM
SANDELL SCOTT D10% OwnerJan 26, 2023 Sale$3.121,351,0924,213,7862,237,196Jan 27, 2023, 05:15 PM
SANDELL SCOTT D10% OwnerJan 26, 2023 Sale$3.121,648,9085,142,6142,730,334Jan 27, 2023, 05:15 PM
SANDELL SCOTT D10% OwnerJan 25, 2023 Sale$3.26293,645958,4283,588,288Jan 27, 2023, 05:15 PM
SANDELL SCOTT D10% OwnerJan 25, 2023 Sale$3.26358,3711,169,6874,379,242Jan 27, 2023, 05:15 PM
SANDELL SCOTT D10% OwnerJan 05, 2023 Sale$2.7632,13988,6593,881,933Jan 06, 2023, 06:35 PM
SANDELL SCOTT D10% OwnerJan 05, 2023 Sale$2.7639,223108,2014,737,613Jan 06, 2023, 06:35 PM
SANDELL SCOTT D10% OwnerDec 30, 2022 Sale$3.0266,690201,4044,928,974Jan 04, 2023, 05:26 PM
SANDELL SCOTT D10% OwnerJan 04, 2023 Sale$2.9145,930133,6433,914,072Jan 04, 2023, 05:26 PM
SANDELL SCOTT D10% OwnerJan 04, 2023 Sale$2.9156,054163,1004,776,836Jan 04, 2023, 05:26 PM
SANDELL SCOTT D10% OwnerJan 03, 2023 Sale$2.9978,730235,4113,960,002Jan 04, 2023, 05:26 PM
SANDELL SCOTT D10% OwnerJan 03, 2023 Sale$2.9996,084287,3014,832,890Jan 04, 2023, 05:26 PM
SANDELL SCOTT D10% OwnerDec 30, 2022 Sale$3.0254,645165,0284,038,732Jan 04, 2023, 05:26 PM
Rock EdwinChief Medical OfficerDec 22, 2022 Buy$2.25110,000247,500310,000Dec 27, 2022, 06:41 PM
JUNIUS DANIEL MDirectorNov 17, 2022 Buy$1.8720,00037,40063,250Nov 18, 2022, 04:01 PM
Rock EdwinChief Medical OfficerNov 15, 2022 Buy$1.66100,000166,000200,000Nov 16, 2022, 04:26 PM
Rock EdwinChief Medical OfficerNov 14, 2022 Buy$1.43100,000143,000100,000Nov 16, 2022, 04:26 PM
PEARSON TIMOTHY RDirectorNov 11, 2022 Buy$1.2919,40025,02624,650Nov 14, 2022, 04:14 PM
Semerjian HaroutChief Executive OfficerNov 11, 2022 Buy$1.2925,00032,25025,000Nov 14, 2022, 04:13 PM
Hahn Brian M.SVP Finance, CFONov 11, 2022 Buy$1.0620,00021,20056,843Nov 14, 2022, 04:13 PM
Magnani John L.SVP of Research, CSONov 11, 2022 Buy$1.1745,04552,703366,078Nov 14, 2022, 04:11 PM
Girard ArmandSVP, Chief Business OfficerNov 11, 2022 Buy$1.056,5006,82529,161Nov 14, 2022, 04:04 PM
Magnani John L.SVP of Research, CSOMar 09, 2022 Sale$1.093,2273,517321,033Mar 10, 2022, 05:06 PM
Girard ArmandSVP, Chief Business OfficerMar 09, 2022 Sale$1.092,3392,55022,661Mar 10, 2022, 05:05 PM
Hahn Brian M.SVP Finance, CFOMar 09, 2022 Sale$1.092,9173,18036,843Mar 10, 2022, 05:03 PM
Andrews Patricia SDirectorNov 16, 2021 Buy$2.0540,00082,00045,250Nov 18, 2021, 04:05 PM
King Rachel K.President, CEODec 28, 2020 Option Exercise$1.12130,821146,520440,240Dec 30, 2020, 04:00 PM
King Rachel K.President, CEODec 28, 2020 Sale$3.9184,176329,128356,064Dec 30, 2020, 04:00 PM
Hahn Brian M.SVP Finance, CFODec 16, 2020 Option Exercise$1.125,2605,8915,260Dec 17, 2020, 04:00 PM
BVF PARTNERS L P/IL10% OwnerNov 04, 2020 Buy$2.601,266,7373,293,5164,980,812Nov 06, 2020, 06:33 PM
BVF PARTNERS L P/IL10% OwnerOct 30, 2020 Buy$2.75932,6122,564,6834,306,320Nov 03, 2020, 04:44 PM
JUNIUS DANIEL MDirectorMar 09, 2020 Buy$3.4020,00068,00038,000Mar 10, 2020, 06:12 PM
Magnani John L.SVP of Research, CSOJan 06, 2020 Option Exercise$1.12106,983119,821289,760Jan 06, 2020, 06:23 PM
Magnani John L.SVP of Research, CSODec 20, 2019 Option Exercise$1.12106,984119,822182,777Dec 23, 2019, 04:13 PM
BVF PARTNERS L P/IL10% OwnerSep 05, 2019 Buy$3.181,668,7465,309,9503,639,935Sep 09, 2019, 04:49 PM
JUNIUS DANIEL MDirectorAug 13, 2019 Buy$3.1810,00031,80018,000Aug 15, 2019, 04:03 PM
King Rachel K.President, CEOAug 06, 2019 Option Exercise$1.12166,759186,770307,144Aug 07, 2019, 04:29 PM
Magnani John L.SVP of Research, CSOOct 17, 2018 Sale$14.007,273101,82279,320Oct 18, 2018, 05:36 PM
Magnani John L.SVP of Research, CSOOct 16, 2018 Sale$14.0114,200198,94286,593Oct 18, 2018, 05:36 PM
Magnani John L.SVP of Research, CSOOct 18, 2018 Sale$14.023,52749,44975,793Oct 18, 2018, 05:36 PM
Hahn Brian M.CFOJun 11, 2018 Option Exercise$1.125,2605,89119,345Jun 12, 2018, 05:54 PM
Hahn Brian M.CFOJun 11, 2018 Sale$18.0419,345348,9840Jun 12, 2018, 05:54 PM
Magnani John L.SVP of Research, CSOMay 23, 2018 Option Exercise$0.331,491492100,793May 24, 2018, 05:11 PM
SANDELL SCOTT D10% OwnerMay 10, 2018 Sale$17.819,539169,8904,995,664May 11, 2018, 05:02 PM
SANDELL SCOTT D10% OwnerMay 10, 2018 Option Exercise$0.33514,452169,7695,001,197May 11, 2018, 05:02 PM
BARRIS PETER J10% OwnerMay 10, 2018 Sale$17.819,539169,8904,995,664May 11, 2018, 05:01 PM
BARRIS PETER J10% OwnerMay 10, 2018 Option Exercise$0.33514,452169,7695,001,197May 11, 2018, 05:01 PM
BARRETT M JAMESDirectorMay 10, 2018 Sale$17.819,539169,8904,995,664May 11, 2018, 05:00 PM
BARRETT M JAMESDirectorMay 10, 2018 Option Exercise$0.33514,452169,7695,001,197May 11, 2018, 05:00 PM
NEW ENTERPRISE ASSOCIATES 10 L P10% OwnerMay 10, 2018 Sale$17.819,539169,8904,995,664May 11, 2018, 05:00 PM
NEW ENTERPRISE ASSOCIATES 10 L P10% OwnerMay 10, 2018 Option Exercise$0.33514,452169,7695,001,197May 11, 2018, 05:00 PM
Thackray Helen M.SVP Clinical Development, CMODec 08, 2017 Sale$15.012,00030,020148,615Dec 12, 2017, 04:14 PM
Thackray Helen M.SVP Clinical Development, CMOSep 18, 2017 Sale$13.002,00026,000150,615Sep 18, 2017, 06:15 PM
JUNIUS DANIEL MDirectorJun 15, 2017 Option Exercise$11.273,00033,8108,000Jun 16, 2017, 05:14 PM
Thackray Helen M.SVP Clinical Development, CMOMay 25, 2017 Sale$15.572,00031,140152,615May 30, 2017, 04:07 PM
Thackray Helen M.SVP Clinical Development, CMOMay 19, 2017 Sale$12.142,00024,280154,615May 22, 2017, 09:23 PM
Magnani John L.SVP of Research, CSOMay 10, 2017 Option Exercise$1.128,9289,99999,302May 11, 2017, 04:00 PM
JUNIUS DANIEL MDirectorDec 20, 2016 Buy$6.015,00030,0505,000Dec 21, 2016, 04:23 PM
Thackray Helen M.VP Clinical Development, CMOOct 03, 2016 Sale$7.004,00028,001156,715Oct 04, 2016, 04:22 PM
Thackray Helen M.VP Clinical Development, CMOJul 20, 2016 Sale$8.002,00016,000160,615Jul 21, 2016, 05:27 PM
Thackray Helen M.VP Clinical Development, CMOJul 06, 2016 Sale$6.686,79645,397162,615Jul 06, 2016, 05:07 PM
Thackray Helen M.VP Clinical Development, CMOJul 05, 2016 Sale$7.0110,13671,053169,411Jul 06, 2016, 05:07 PM
Thackray Helen M.VP Clinical Development, CMOJul 01, 2016 Sale$7.405,06837,503179,547Jul 06, 2016, 05:07 PM
Baldwin John J.DirectorJun 29, 2016 Option Exercise$1.126056781,210Jul 01, 2016, 11:43 AM
Goldberg Mark AlanDirectorMar 04, 2016 Buy$4.7710,39749,63011,497Mar 07, 2016, 08:03 AM
TOP FRANKLIN H JRDirectorFeb 05, 2016 Option Exercise$1.1211,68913,09212,294Feb 12, 2016, 03:30 PM
SANDELL SCOTT D10% OwnerNov 16, 2015 Sale$6.914523,1234,490,751Nov 18, 2015, 02:20 PM
SANDELL SCOTT D10% OwnerNov 16, 2015 Option Exercise$0.339,4453,1174,491,203Nov 18, 2015, 02:20 PM
BARRIS PETER J10% OwnerNov 16, 2015 Sale$6.914523,1234,490,751Nov 18, 2015, 02:20 PM
BARRIS PETER J10% OwnerNov 16, 2015 Option Exercise$0.339,4453,1174,491,203Nov 18, 2015, 02:20 PM
BARRETT M JAMESDirectorNov 16, 2015 Sale$6.914523,1234,490,751Nov 18, 2015, 02:19 PM
BARRETT M JAMESDirectorNov 16, 2015 Option Exercise$0.339,4453,1174,491,203Nov 18, 2015, 02:19 PM
NEW ENTERPRISE ASSOCIATES 10 L P10% OwnerNov 16, 2015 Sale$6.914523,1234,490,751Nov 18, 2015, 02:18 PM
NEW ENTERPRISE ASSOCIATES 10 L P10% OwnerNov 16, 2015 Option Exercise$0.339,4453,1174,491,203Nov 18, 2015, 02:18 PM
Hahn Brian M.CFOFeb 27, 2015 Option Exercise$1.125,0005,60014,085Mar 03, 2015, 04:08 PM
King Rachel K.President, CEOFeb 24, 2015 Option Exercise$1.1250,00056,000167,206Feb 26, 2015, 05:02 PM
HENOS MICHAEL ADirectorDec 22, 2014 Sale$8.4410,65989,913469,454Dec 23, 2014, 04:30 PM
HENOS MICHAEL ADirectorDec 19, 2014 Sale$8.6110,59891,277480,113Dec 23, 2014, 04:30 PM
HENOS MICHAEL ADirectorDec 17, 2014 Sale$8.975,12145,935490,711Dec 17, 2014, 06:10 PM
HENOS MICHAEL ADirectorDec 15, 2014 Sale$8.981,60414,404495,832Dec 17, 2014, 06:10 PM
HENOS MICHAEL ADirectorDec 15, 2014 Option Exercise$0.3343,62814,397497,436Dec 17, 2014, 06:10 PM
King Rachel K.President, CEOJun 18, 2014 Option Exercise$1.12100,000112,000108,706Jun 20, 2014, 04:00 PM
HENOS MICHAEL ADirectorJun 13, 2014 Buy$6.215,00031,05012,562Jun 13, 2014, 04:01 PM
HENOS MICHAEL ADirectorJun 12, 2014 Buy$6.546,00039,2407,562Jun 13, 2014, 04:01 PM
HENOS MICHAEL ADirectorApr 03, 2014 Option Exercise$1.121,5621,7491,562Apr 03, 2014, 04:38 PM
BARRIS PETER J10% OwnerJan 15, 2014 Buy$8.00512,5004,100,0004,093,377Jan 15, 2014, 05:16 PM
BARRIS PETER J10% OwnerJan 15, 2014 Buy$8.00487,5003,900,0004,481,758Jan 15, 2014, 05:16 PM
SANDELL SCOTT D10% OwnerJan 15, 2014 Buy$8.00512,5004,100,0004,093,377Jan 15, 2014, 05:15 PM
SANDELL SCOTT D10% OwnerJan 15, 2014 Buy$8.00487,5003,900,0004,481,758Jan 15, 2014, 05:15 PM
BARRETT M JAMESDirectorJan 15, 2014 Buy$8.00512,5004,100,0004,093,377Jan 15, 2014, 05:15 PM
BARRETT M JAMESDirectorJan 15, 2014 Buy$8.00487,5003,900,0004,481,758Jan 15, 2014, 05:15 PM
NEW ENTERPRISE ASSOCIATES 13 LP10% OwnerJan 15, 2014 Buy$8.00512,5004,100,0004,093,377Jan 15, 2014, 05:14 PM
NEW ENTERPRISE ASSOCIATES 10 L P10% OwnerJan 15, 2014 Buy$8.00487,5003,900,0004,481,758Jan 15, 2014, 05:13 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Andrews Patricia SDirector12/29/202312,251
King Rachel K.Director12/29/202310,002
Goldberg Mark AlanDirector12/29/202313,752
Goldberg Mark AlanDirector09/30/202313,751
Rock EdwinChief Medical Officer09/22/202341,956
Rock EdwinChief Medical Officer09/21/202348,300
Koenig ScottDirector06/01/202312,600
Hahn Brian M.SVP Finance, CFO05/17/20237,215
JUNIUS DANIEL MDirector05/10/202346,800
Johnson Bruce SSVP & Chief Commercial Officer05/08/202321,195
Invus Public Equities, L.P.10% Owner02/24/2023170,000
Invus Public Equities, L.P.10% Owner02/23/2023350,760
Invus Public Equities, L.P.10% Owner02/22/2023268,995
Invus Public Equities, L.P.10% Owner02/21/202392,500
Invus Public Equities, L.P.10% Owner02/17/2023341,000
Invus Public Equities, L.P.10% Owner02/16/2023531,129
Invus Public Equities, L.P.10% Owner02/15/20232,155,800
Invus Public Equities, L.P.10% Owner02/09/202337,123
Koenig ScottDirector01/27/202326,775
SANDELL SCOTT D10% Owner01/26/20234,213,786
SANDELL SCOTT D10% Owner01/26/20235,142,614
SANDELL SCOTT D10% Owner01/25/2023958,428
SANDELL SCOTT D10% Owner01/25/20231,169,687
SANDELL SCOTT D10% Owner01/05/202388,659
SANDELL SCOTT D10% Owner01/05/2023108,201
SANDELL SCOTT D10% Owner12/30/2022201,404
SANDELL SCOTT D10% Owner01/04/2023133,643
SANDELL SCOTT D10% Owner01/04/2023163,100
SANDELL SCOTT D10% Owner01/03/2023235,411
SANDELL SCOTT D10% Owner01/03/2023287,301
SANDELL SCOTT D10% Owner12/30/2022165,028
Rock EdwinChief Medical Officer12/22/2022247,500
JUNIUS DANIEL MDirector11/17/202237,400
Rock EdwinChief Medical Officer11/15/2022166,000
Rock EdwinChief Medical Officer11/14/2022143,000
PEARSON TIMOTHY RDirector11/11/202225,026
Semerjian HaroutChief Executive Officer11/11/202232,250
Hahn Brian M.SVP Finance, CFO11/11/202221,200
Magnani John L.SVP of Research, CSO11/11/202252,703
Girard ArmandSVP, Chief Business Officer11/11/20226,825
Magnani John L.SVP of Research, CSO03/09/20223,517
Girard ArmandSVP, Chief Business Officer03/09/20222,550
Hahn Brian M.SVP Finance, CFO03/09/20223,180
Andrews Patricia SDirector11/16/202182,000
King Rachel K.President, CEO12/28/2020146,520
King Rachel K.President, CEO12/28/2020329,128
Hahn Brian M.SVP Finance, CFO12/16/20205,891
BVF PARTNERS L P/IL10% Owner11/04/20203,293,516
BVF PARTNERS L P/IL10% Owner10/30/20202,564,683
JUNIUS DANIEL MDirector03/09/202068,000
Magnani John L.SVP of Research, CSO01/06/2020119,821
Magnani John L.SVP of Research, CSO12/20/2019119,822
BVF PARTNERS L P/IL10% Owner09/05/20195,309,950
JUNIUS DANIEL MDirector08/13/201931,800
King Rachel K.President, CEO08/06/2019186,770
Magnani John L.SVP of Research, CSO10/17/2018101,822
Magnani John L.SVP of Research, CSO10/16/2018198,942
Magnani John L.SVP of Research, CSO10/18/201849,449
Hahn Brian M.CFO06/11/20185,891
Hahn Brian M.CFO06/11/2018348,984
Magnani John L.SVP of Research, CSO05/23/2018492
SANDELL SCOTT D10% Owner05/10/2018169,890
SANDELL SCOTT D10% Owner05/10/2018169,769
BARRIS PETER J10% Owner05/10/2018169,890
BARRIS PETER J10% Owner05/10/2018169,769
BARRETT M JAMESDirector05/10/2018169,890
BARRETT M JAMESDirector05/10/2018169,769
NEW ENTERPRISE ASSOCIATES 10 L P10% Owner05/10/2018169,890
NEW ENTERPRISE ASSOCIATES 10 L P10% Owner05/10/2018169,769
Thackray Helen M.SVP Clinical Development, CMO12/08/201730,020
Thackray Helen M.SVP Clinical Development, CMO09/18/201726,000
JUNIUS DANIEL MDirector06/15/201733,810
Thackray Helen M.SVP Clinical Development, CMO05/25/201731,140
Thackray Helen M.SVP Clinical Development, CMO05/19/201724,280
Magnani John L.SVP of Research, CSO05/10/20179,999
JUNIUS DANIEL MDirector12/20/201630,050
Thackray Helen M.VP Clinical Development, CMO10/03/201628,001
Thackray Helen M.VP Clinical Development, CMO07/20/201616,000
Thackray Helen M.VP Clinical Development, CMO07/06/201645,397
Thackray Helen M.VP Clinical Development, CMO07/05/201671,053
Thackray Helen M.VP Clinical Development, CMO07/01/201637,503
Baldwin John J.Director06/29/2016678
Goldberg Mark AlanDirector03/04/201649,630
TOP FRANKLIN H JRDirector02/05/201613,092
SANDELL SCOTT D10% Owner11/16/20153,123
SANDELL SCOTT D10% Owner11/16/20153,117
BARRIS PETER J10% Owner11/16/20153,123
BARRIS PETER J10% Owner11/16/20153,117
BARRETT M JAMESDirector11/16/20153,123
BARRETT M JAMESDirector11/16/20153,117
NEW ENTERPRISE ASSOCIATES 10 L P10% Owner11/16/20153,123
NEW ENTERPRISE ASSOCIATES 10 L P10% Owner11/16/20153,117
Hahn Brian M.CFO02/27/20155,600
King Rachel K.President, CEO02/24/201556,000
HENOS MICHAEL ADirector12/22/201489,913
HENOS MICHAEL ADirector12/19/201491,277
HENOS MICHAEL ADirector12/17/201445,935
HENOS MICHAEL ADirector12/15/201414,404
HENOS MICHAEL ADirector12/15/201414,397
King Rachel K.President, CEO06/18/2014112,000
HENOS MICHAEL ADirector06/13/201431,050
HENOS MICHAEL ADirector06/12/201439,240
HENOS MICHAEL ADirector04/03/20141,749
BARRIS PETER J10% Owner01/15/20144,100,000
BARRIS PETER J10% Owner01/15/20143,900,000
SANDELL SCOTT D10% Owner01/15/20144,100,000
SANDELL SCOTT D10% Owner01/15/20143,900,000
BARRETT M JAMESDirector01/15/20144,100,000
BARRETT M JAMESDirector01/15/20143,900,000
NEW ENTERPRISE ASSOCIATES 13 LP10% Owner01/15/20144,100,000
NEW ENTERPRISE ASSOCIATES 10 L P10% Owner01/15/20143,900,000
Load More Insider Transactions
FUNDS WITH A POSITION IN GLYCOMIMETICS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.734,9830.00004%0.04%Other
GEODE CAPITAL MANAGEMENT, LLC478,8830.00012%4.14%Other
RENAISSANCE TECHNOLOGIES LLC124,4440.00046%-38.12%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.100,0000.00049%NewOther
CHANGE IN SHARES OUTSTANDING FOR GLYCOMIMETICS INC
STOCK BUYBACKS FOR GLYCOMIMETICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2023
06/30/2023
0.11%
1Q
09/30/2023
03/31/2023
6.63%
2Q
09/30/2023
12/31/2022
21.50%
3Q
09/30/2023
09/30/2022
22.75%
4Q
09/30/2023
06/30/2022
22.79%
5Q
09/30/2023
03/31/2022
22.97%
6Q
09/30/2023
12/31/2021
23.72%
7Q
09/30/2023
09/30/2021
24.79%
8Q
09/30/2023
06/30/2021
24.86%
9Q
09/30/2023
03/31/2021
26.93%
10Q
09/30/2023
12/31/2020
34.07%
11Q
09/30/2023
09/30/2020
35.44%
12Q
09/30/2023
06/30/2020
46.91%
13Q
09/30/2023
03/31/2020
47.67%
14Q
09/30/2023
12/31/2019
48.36%
15Q
09/30/2023
09/30/2019
48.63%
16Q
Load More

Period of Report: 09/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2023
0.11%
1Q
03/31/2023
6.63%
2Q
12/31/2022
21.50%
3Q
09/30/2022
22.75%
4Q
06/30/2022
22.79%
5Q
03/31/2022
22.97%
6Q
12/31/2021
23.72%
7Q
09/30/2021
24.79%
8Q
06/30/2021
24.86%
9Q
03/31/2021
26.93%
10Q
12/31/2020
34.07%
11Q
09/30/2020
35.44%
12Q
06/30/2020
46.91%
13Q
03/31/2020
47.67%
14Q
12/31/2019
48.36%
15Q
09/30/2019
48.63%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR GLYCOMIMETICS INC
LOADING...